CASI Pharmaceuticals, Inc.

CASI

KYG1933S1012

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.42 ^USD	+5.22%		+7.56%	-66.20%

Mar. 28	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	Top Midday Gainers	MT

CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd

February 29, 2024 at 04:14 pm EST

On February 28, 2024, CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals (China) Co. Ltd. entered into a 3-year renewal agreement for certain Exclusive Distribution Agreement dated March 2, 2022, effective as of March 2, 2024, with China Resources Pharmaceutical Commercial Group International Trading Co. Ltd. (CRPCGIT).

Under the terms of the Agreement, the parties have agreed to extend the term of the Exclusive Distribution Agreement for three years. Other terms and conditions of the Exclusive Distribution Agreement remain in full force and effect without change.

Latest news about CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Top Midday Gainers	Mar. 05	MT
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell	Mar. 05	MT
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Mar. 05	MT
Top Premarket Gainers	Mar. 05	MT
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China	Mar. 05	CI
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd	Feb. 29	CI
Casi Pharmaceuticals Announces First Dose of Folotyn in China	Feb. 16	CI
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer	Feb. 12	CI
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer	Jan. 30	CI
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd	Dec. 08	CI
HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating	Nov. 15	MT
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q3 Revenue $8.8M	Nov. 14	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q2 Revenue $9.8M	23-08-11	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
CASI Pharmaceuticals Acquires Intellectual Property Rights to Cleave Therapeutics' Drug Candidate CB-5339	23-07-20	MT
CASI Pharmaceuticals, Inc.(NasdaqCM:CASI) dropped from S&P TMI Index	23-06-20	CI
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q1 Revenue $8.3M	23-05-17	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q4 Revenue $43.1M	23-04-26	MT
North American Morning Briefing : Focus Turns to -2-	23-04-10	DJ
North American Morning Briefing : Stock Futures -2-	23-03-27	DJ
CASI Pharmaceuticals Completes Redomiciliation Merger	23-03-21	MT

Chart CASI Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Companyâs Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Sector

Pharmaceuticals

Calendar

2024-05-19 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for CASI Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.42 USD

Average target price

12 USD

Spread / Average Target

+395.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CASI PHARMACEUTICALS, INC.	-66.20%	31.43M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals